Only 56% of sponsors & CROs report decentralised clinical trials (DCTs) had a positive impact on patient convenience & retention
16 Jan 2023, 13:00
Only 56% of sponsors & CROs report decentralised clinical trials (DCTs) had a positive impact on patient convenience & retention.
This is because DCTs often introduce multiple patient-facing applications, thereby adding complexity for patients.
Source:
Same news in other sources
2
16 Jan 2023, 13:49
Fact of the day š
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience and retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Triall addresses this issue by offering a single unified platform with integrated eConsent, ePRO, and virtual visits tools. This ensures patients only need to use a single application throughout the study.
Source:
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
Fact of the day š
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience and retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Triall addresses this issue by offering a single unified platform with integrated eConsent, ePRO, and virtual visits tools. This ensures patients only need to use a single application throughout the study.
Source: https://eu1.hubs.ly/H02BnpN0
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1614970727903514636?s=20&t=H9oRtPantadrgPro-71xKg
#blockchainforhealth #TRL
16 Jan 2023, 13:48
Fact of the day š
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience and retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Triall addresses this issue by offering a single unified platform with integrated eConsent, ePRO, and virtual visits tools. This ensures patients only need to use a single application throughout the study.
Source:
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
#blockchainforhealth #TRL
Fact of the day.
Fact of the day š
Only 56% of sponsors and CROs report decentralised trials have had a positive impact on patient convenience and retention.
The most commonly heard argument is that decentralised trials often introduce multiple patient-facing applications, thereby adding unnecessary complexity for patients.
Triall addresses this issue by offering a single unified platform with integrated eConsent, ePRO, and virtual visits tools. This ensures patients only need to use a single application throughout the study.
Source: https://eu1.hubs.ly/H02BnpN0
ā”ļø Trade $TRL at bit.ly/tradeTRL
š£ Help us spread the news on Twitter:
https://twitter.com/triallofficial/status/1614970727903514636?s=20&t=H9oRtPantadrgPro-71xKg
#blockchainforhealth #TRL